drugset / Trial / NCT00058487
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
Open-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide in treating patients who have unresectable or metastatic liver cancer.
Timeline
- Start
- 2001-12
- Primary completion
- —
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |